{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361981469716084352.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1124/jpet.117.247551"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0022356524267896?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0022356524267896?httpAccept=text/plain"}},{"identifier":{"@type":"URI","@value":"https://syndication.highwire.org/content/doi/10.1124/jpet.117.247551"}}],"dc:title":[{"@value":"Binding Characteristics and Analgesic Effects of Mirogabalin, a Novel Ligand for the α2δ Subunit of Voltage-Gated Calcium Channels"}],"description":[{"notation":[{"@value":"Mirogabalin ([(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid), a novel ligand for the α2δ subunit of voltage-gated calcium channels, is being developed to treat pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. In the present study, we investigated the in vitro binding characteristics and in vivo analgesic effects of mirogabalin compared with those of pregabalin, a standard α2δ ligand. Mirogabalin showed potent and selective binding affinities for the α2δ subunits, while having no effects on 186 off-target proteins. Similar to pregabalin, mirogabalin did not show clear subtype selectivity (α2δ-1 vs. α2δ-2) or species differences (human vs. rat). However, in contrast to pregabalin, mirogabalin showed greater binding affinities for human α2δ-1, human α2δ-2, rat α2δ-1, and rat α2δ-2 subunits; further, it had a slower dissociation rate for the α2δ-1 subunit than the α2δ-2 subunit. Additionally, in experimental neuropathic pain models, partial sciatic nerve ligation rats and streptozotocin-induced diabetic rats, mirogabalin showed more potent and longer lasting analgesic effects. In safety pharmacological evaluations, mirogabalin and pregabalin inhibited rota-rod performance and locomotor activity in rats; however, the safety indices of mirogabalin were superior to those of pregabalin. In conclusion, mirogabalin shows potent and selective binding affinities for the human and rat α2δ subunits, and slower dissociation rates for the α2δ-1 subunit than the α2δ-2 subunit. It shows potent and long-lasting analgesic effects in rat models of neuropathic pain, and wider safety margins for side effects of the central nervous system. These properties of mirogabalin can be associated with its unique binding characteristics."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381981469716084355","@type":"Researcher","foaf:name":[{"@value":"Yuki Domon"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469716084359","@type":"Researcher","foaf:name":[{"@value":"Naohisa Arakawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469716084358","@type":"Researcher","foaf:name":[{"@value":"Tatsuya Inoue"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469716084353","@type":"Researcher","foaf:name":[{"@value":"Fumihiko Matsuda"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469716084356","@type":"Researcher","foaf:name":[{"@value":"Makoto Takahashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469716084354","@type":"Researcher","foaf:name":[{"@value":"Naotoshi Yamamura"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469716084352","@type":"Researcher","foaf:name":[{"@value":"Kiyonori Kai"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469716084357","@type":"Researcher","foaf:name":[{"@value":"Yutaka Kitano"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00223565"},{"@type":"EISSN","@value":"15210103"}],"prism:publicationName":[{"@value":"The Journal of Pharmacology and Experimental Therapeutics"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2018-06","prism:volume":"365","prism:number":"3","prism:startingPage":"573","prism:endingPage":"582"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license","http://creativecommons.org/licenses/by/4.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0022356524267896?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0022356524267896?httpAccept=text/plain"},{"@id":"https://syndication.highwire.org/content/doi/10.1124/jpet.117.247551"}],"createdAt":"2018-03-21","modifiedAt":"2025-02-19","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360013168763864960","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Switching From Pregabalin to Mirogabalin in Patients with Peripheral Neuropathic Pain: A Multi-Center, Prospective, Single-Arm, Open-Label Study (MIROP Study)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360017280666081280","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Symptom-based pharmacotherapy for neuropathic pain related to spinal disorders: results from a patient-based assessment"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021390758445056","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298757165167104","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Recognition Mechanism of a Novel Gabapentinoid Drug, Mirogabalin, for Recombinant Human α2δ1, a Voltage-Gated Calcium Channel Subunit"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298757188560128","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Analgesic characteristics of a newly developed α<sub>2</sub>δ ligand, mirogabalin, on inflammatory pain"}]},{"@id":"https://cir.nii.ac.jp/crid/1360303976322114432","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Mirogabalin inhibits scratching behavior of spontaneous model mouse of atopic dermatitis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360306904398581632","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prescribing Cascades of Loop Diuretics and Anti-vertigo Drugs Following Treatment with Gabapentinoids and Benzodiazepines: Prescription Sequence Symmetry Analysis of a Large-Scale Claims Database Including Japanese Older Adults"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580232405542912","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Treatment Options for Troublesome Itch"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584341815788288","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of drug therapy for the prevention and treatment of chemotherapy-induced peripheral neuropathy: a protocol for a systematic review and network meta-analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857690435642496","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Mirogabalin alleviates nociceptive hypersensitivity without causing sedation in a mouse model of post-traumatic trigeminal neuropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360869856038002432","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Mirogabalin and pregabalin alleviate nociplastic sensitization induced by chemogenetic activation of the central amygdala neurons in rodents"}]},{"@id":"https://cir.nii.ac.jp/crid/1390009294965088768","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Efficacy Evaluation of Mirogabalin for Chemotherapy-induced Peripheral Neuropathy"},{"@language":"ja","@value":"抗がん薬に伴う末梢神経障害に対するミロガバリンの有効性評価"}]},{"@id":"https://cir.nii.ac.jp/crid/1390303697453856384","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Adverse events, including fractures, among older patients receiving mirogabalin versus pregabalin: A retrospective cohort study using a large claims database in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1390845702329636736","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Pharmacological, pharmacodynamics, and clinical profile of mirogabalin besylate (Tarlige<sup>®</sup> tablets 2.5 mg∙5 mg∙10 mg∙15 mg)"},{"@language":"ja","@value":"ミロガバリンベシル酸塩（タリージェ<sup>®</sup>錠2.5 mg・5 mg・10 mg・15 mg）の薬理学的および薬物動態学的特性と臨床試験成績"},{"@value":"新薬紹介総説 ミロガバリンベシル酸塩(タリージェ錠2.5 mg・5 mg・10 mg・15 mg)の薬理学的および薬物動態学的特性と臨床試験成績"},{"@language":"ja-Kana","@value":"シンヤク ショウカイ ソウセツ ミロガバリンベシル サンエン(タリージェジョウ 2.5 mg ・ 5 mg ・ 10 mg ・ 15 mg)ノ ヤクリガクテキ オヨビ ヤクブツ ドウタイガクテキ トクセイ ト リンショウ シケン セイセキ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390858518830987136","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Clinical Outcomes of Mirogabalin Treatment for Neuropathic Pain Due to Spinal Diseases in Patients Intolerant to Continuous Administration of Pregabalin"}]},{"@id":"https://cir.nii.ac.jp/crid/1391694356245735552","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Treatment of Chronic Postsurgical Pain in Pain Medicine"},{"@language":"ja","@value":"ペインクリニックで診る遷延性術後痛"}]},{"@id":"https://cir.nii.ac.jp/crid/1391975276382471936","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Frequency of Adverse Drug Reactions and Analgesic Effects of Mirogabalin during Treatment of Peripheral Neuropathic Pain: A Retrospective Clinical Investigation"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1124/jpet.117.247551"},{"@type":"OPENAIRE","@value":"doi_dedup___::cbd52ff3ebbcbbf747682a125742faa3"},{"@type":"CROSSREF","@value":"10.1007/s40122-021-00255-y_references_DOI_QHztxSYblcCse85X9AE7H9FsCtw"},{"@type":"CROSSREF","@value":"10.1038/s41598-022-11345-y_references_DOI_QHztxSYblcCse85X9AE7H9FsCtw"},{"@type":"CROSSREF","@value":"10.1186/s12885-023-11560-4_references_DOI_QHztxSYblcCse85X9AE7H9FsCtw"},{"@type":"CROSSREF","@value":"10.37737/ace.25008_references_DOI_QHztxSYblcCse85X9AE7H9FsCtw"},{"@type":"CROSSREF","@value":"10.3389/fphar.2024.1382281_references_DOI_QHztxSYblcCse85X9AE7H9FsCtw"},{"@type":"CROSSREF","@value":"10.1254/fpj.154.352_references_DOI_QHztxSYblcCse85X9AE7H9FsCtw"},{"@type":"CROSSREF","@value":"10.22603/ssrr.2022-0127_references_DOI_QHztxSYblcCse85X9AE7H9FsCtw"},{"@type":"CROSSREF","@value":"10.1016/j.jmb.2023.168049_references_DOI_QHztxSYblcCse85X9AE7H9FsCtw"},{"@type":"CROSSREF","@value":"10.1177/17448069211052167_references_DOI_QHztxSYblcCse85X9AE7H9FsCtw"},{"@type":"CROSSREF","@value":"10.1007/s40801-024-00446-x_references_DOI_QHztxSYblcCse85X9AE7H9FsCtw"},{"@type":"CROSSREF","@value":"10.3390/ph15081022_references_DOI_QHztxSYblcCse85X9AE7H9FsCtw"},{"@type":"CROSSREF","@value":"10.1136/bmjopen-2022-070645_references_DOI_QHztxSYblcCse85X9AE7H9FsCtw"},{"@type":"CROSSREF","@value":"10.2199/jjsca.40.609_references_DOI_QHztxSYblcCse85X9AE7H9FsCtw"},{"@type":"CROSSREF","@value":"10.5649/jjphcs.47.1_references_DOI_QHztxSYblcCse85X9AE7H9FsCtw"},{"@type":"CROSSREF","@value":"10.1016/j.bbr.2022.113829_references_DOI_QHztxSYblcCse85X9AE7H9FsCtw"},{"@type":"CROSSREF","@value":"10.1016/j.jphs.2025.03.004_references_DOI_QHztxSYblcCse85X9AE7H9FsCtw"},{"@type":"CROSSREF","@value":"10.22603/ssrr.2020-0042_references_DOI_QHztxSYblcCse85X9AE7H9FsCtw"}]}